420 with CNW — Immigrants Still Face Legal Consequences for Marijuana Use Despite State-Level Legalization

In Minnesota, individuals aged 21 years and older are permitted to legally possess and use marijuana. However, despite being legal at the state level, marijuana remains prohibited under federal law. This legal nuance is particularly pertinent for immigrants who haven’t obtain U.S. citizenship, according to Julia Decker, the policy director at the Immigrant Law Center of Minnesota.

Decker emphasizes the federal control over cannabis, noting that engaging in any related activities or possessing marijuana could result in immigration consequences, potentially leading to deportation. This distinction holds regardless of one’s legal status, even if an individual possesses a green card or other lawful immigration documentation.

The complexity arises because, under Minnesota state law, an individual might possess a small quantity of cannabis for personal use without facing criminal charges. However, immigration applications often inquire about any uncharged or unconvicted criminal acts, complicating matters for applicants swearing under penalty of perjury or oath. Even in the absence of a criminal case, Decker warns of potential consequences.

Linus Chan, a clinical professor of law at the University of Minnesota Law School, points out the challenge attorneys face in navigating a system where the distinction between state and federal law isn’t always clear. He notes that people often overlook the difference between state and federal law when determining whether an act constitutes a crime. This lack of clarity extends to areas such as conviction expungements, where a state expungement may not carry weight at the federal level.

The federal immigration law, as Chan points out, provides no exceptions for medically prescribed cannabis or employment at a dispensary. Although a marijuana conviction doesn’t automatically hinder naturalization or trigger deportation, the risks are heightened for individuals lacking citizenship, according to both Chan and Decker.

Decker underscores the necessity of recognizing the arbitrary nature of legal distinctions, especially concerning marijuana laws. She suggests that, particularly in the context of citizens versus noncitizens, the disparities in legal standards can seem fundamentally unfair across various issues.

As cannabis legalization in Minnesota is still in its early stages, Decker recommends individuals navigating the immigration system seek advice from immigration lawyers. Meanwhile, legal experts closely monitor how these changes may impact the future citizenship prospects of Minnesota residents.

The shifting legal landscape prompts a proactive approach for immigrants, ensuring they comprehend the nuances and potential ramifications within the complex intersection of state, federal and immigration law.

These legal contradictions between federal and state law also create complexities for marijuana companies, such as Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF), as they conduct their legitimate operations.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

CannabisNewsBreaks – Sustain Southern California Names IBN as Media Sponsor for Upcoming Sustainability Private Capital Event

Sustain Southern California (Sustain SoCal), a nonprofit organization, announced that InvestorBrandNetwork (“IBN”), a leading corporate communications firm and content distributor, will be the official media sponsor for the sixth annual Sustainability Private Capital Event. The event, scheduled for Dec. 6–7, 2023, will be hosted by Sustain SoCal and Roth MKM. The conference agenda features some 40 companies as well as experts from an array of sectors, including solar/storage, e-mobility, smart cities, circular economy and water, with most of the companies being in the series A/B fundraising stage. Participating investors include venture capitalists, private equity offices, family offices, representatives of endowments and foundations, and angel investors. As the event media sponsor, IBN will leverage its full suite of corporate communications solutions to enhance visibility and recognition for panel speakers, participating companies and the event itself. Through its events, Sustain SoCal has earned a reputation for being a leading information hub, advocacy and networking platform as well as educational forum committed to advancing discourse and actions on economic progress and sustainable environmental development in Southern California and the surrounding regions.

ROTH MKM is a privately owned investment banking firm that has gained a reputation for its premier suite of business lines, including M&A, financing, restructuring, advisory, and corporate services. “We are always pleased to partner with both Sustain SoCal and ROTH MKM,” said IBN communications director Jonathan Keim in the press release. “It is a pleasure to work alongside their highly professional teams and to actively connect our investor audiences with the events they produce.”

To learn more about the event, visit https://cnw.fm/4uwhE

To view the full press release, visit https://cnw.fm/byTYE

About Sustain SoCal

Sustain SoCal, a nonprofit organization, accelerates sustainability and economic growth through innovation, collaboration and education in Southern California. The organization has a 10-year history of exploring and implementing pragmatic, real-world solutions to the challenges created by growth, change and inefficiency. The company conducts conferences, workshops and networking events that lead to initiatives that positively impact the region’s economic progress and sustainability. For more information, visit the company’s website at www.SustainSoCal.org.

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Colorado Researchers Search for Reliable Cannabis Breathalyzer

Researchers at the University of Colorado Boulder are on the hunt for a reliable cannabis breathalyzer. Dozens of states now allow access to medical or recreational cannabis, but law enforcement institutions in the United States have largely been against cannabis reform efforts.

On top of complicating law-enforcement efforts, these institutions say legalization will increase driving under the influence rates across the country. While data from several states shows no correlation between cannabis reform and higher traffic incident rates, the lack of a proper cannabis drug test is a major issue.

The breathalyzer has a long history of accurately testing alcohol levels on-site, but we still don’t have tests that can check cannabis intoxication rates. Now that tens of millions of Americans have access to marijuana, there is an urgent need for reliable cannabis breathalyzers to aid in the policing of driving under the influence and prevent nonintoxicated people from being penalized due to inaccurate tests.

Current tools regularly fail to provide accurate blood cannabis levels and often cannot correlate these levels with intoxication at the moment, meaning Americans can be penalized for having THC in their blood even if they aren’t necessarily intoxicated at the moment. The lack of proper tools has left many law enforcement officials searching for a way forward.

Sgt. Roger Meyers from the Colorado State Patrol says the agency has decided not to use the cannabis breathalyzers currently on the market. University of Colorado Boulder associate professor of cognitive science Cinnamon Bidwell says the tools currently in use simply aren’t a good system. He says researchers at the university are working to develop a reliable tool as fast as they can to meet market demand for a marijuana breathalyzer. According to an initial report from a new study, the development of such a tool is gaining promise in terms of gaining scientific information and using the device to help make law enforcement in transportation safe and fair.

Bidwell says that the potential for roadside testing will be incredibly critical for public safety but explains that it will take a lot of research steps before scientists can even establish if a marijuana breathalyzer will be suitable for use by public safety officers. He explains that comparing a marijuana breathalyzer with an alcohol breathalyzer is akin to likening apples to pinecones because only very small amounts of cannabis remain in the body after ingestion.

The fact that marijuana stays in the system longer also makes it difficult to determine a timeline of consumption, especially in people who consume the drug regularly. An accurate test would require plenty of work from the ground up to learn how different cannabis strains affect people, to share this knowledge to troopers and to develop tools that can accurately test cannabis intoxication levels.

The entire cannabis industry, including major companies such as Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), would welcome a reliable way to identify people who are driving while intoxicated or those who use cannabis while at work. This would prevent innocent people from being victimized for false positives arising from cannabis use that occurred days or even months prior.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Public Transit Groups Urge DHHS to Certify Firms Conducting Saliva Tests for Cannabis

U.S. public transit organizations are urging the Department of Health & Human Services (HHS) to implement a system for utilizing saliva tests in drug screenings, specifically for cannabis and other substances. Advocates argue that this method is less invasive compared to traditional urine tests and provides a more accurate reflection of recent drug consumption, preventing individuals from facing consequences for substance use that occurred up to a month before testing.

The U.S. Department of Transportation (DOT) recently changed regulations to allow federally regulated transportation workers such as truckers, pilots and commercial drivers to employ oral fluid testing instead of urine drug testing. HHS has not yet certified saliva-screening laboratories or approved appropriate equipment for on-site saliva collection, despite the regulatory change.

The American Public Transportation Association (APTA) recently sent a letter to Xavier Becerra, the HHS secretary, urging the HHS to expedite the certification of testing labs. In a recent notice, HHS acknowledged the absence of certified laboratories capable of conducting drug-validity testing on oral-fluid specimens. According to APTA, the FDA, an arm of HHS, is also responsible for authorizing a minimum of one oral-fluid collection device to guarantee adherence to the DOT regulation concerning the oral-fluid testing system.

APTA, representing both private and public organizations employing about 430,000 individuals, outlined the advantages of oral-fluid drug testing. These include a less intrusive collection option that is gender neutral, eliminating the use of secured bathrooms. Additionally, saliva-based testing makes it possible to detect more recent drug use, which is important in situations involving post accident testing. The possibility of manipulation or intervention is also diminished by the transparency of the collection procedure.

The benefits were also underscored by the Albuquerque Transit Advisory Board, New Mexico, highlighting its gender-neutral collecting method and quicker identification of recent marijuana usage than urine testing.

In a recent meeting, the board urged the state’s congressional delegation to put pressure on HHS to approve at least two laboratories for oral-fluid testing. In addition, it requested that the city of Albuquerque amend its policy to incorporate oral testing and adhere to federal regulations mandating the use of oral fluid testing for direct observational testing of nonbinary and transgender staff members.

In a separate correspondence, the board urged Becerra to speed up the certification procedure for laboratories. The letter underlined how critical it is to solve the nation’s bus-driver crisis and allow agencies to hire and retain more mechanics and operators. It emphasized the necessity of striking a balance between safety concerns and the changing legal and societal context of drug usage.

With easily accessible certified labs that can accurately establish recent cannabis consumption, more people will be less hesitate to consume marijuana products from numerous companies such as Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY) while off duty because they won’t be victimized under the mistaken belief that they were under the influence while at work when an accident occurred.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Interim Results in Ongoing GLP-1 Human Pilot Study

Lexaria, a global innovator in drug delivery platforms, just announced additional positive interim results from its ongoing GLP-1 human pilot study
The study seeks to provide an early-stage indication of whether DehydraTECH(TM) processing could improve oral drug delivery characteristics of the GLP-1 drug semaglutide
Lexaria’s DehydraTECH GLP-1 showed a 2.9% to 14.6% blood glucose level reduction relative to baseline, compared to 1.3% to 6.7% for the control group
The DehydraTECH GLP-1 group also only saw a 5.3% spike in glucose levels after having a standardized meal at the 240-minute mark and a snack at the 360-minute mark, compared to 22.7% for the control group

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced additional positive interim results from its ongoing human pilot study that seeks to provide an early-stage indication of whether DehydraTECH(TM) processing could improve oral drug delivery characteristics of the GLP-1 drug semaglutide. The study, which focused on Rybelsus(R), a commercially available semaglutide drug, involved seven healthy subjects, four of whom received the DehydraTECH GLP-1, with the other three receiving the control (https://cnw.fm/kr4Ic).

Of note was DehydraTECH GLP-1’s 2.9% to 14.6% blood glucose level reduction relative to baseline, compared to 1.3% to 6.7% for the control group. These results were achieved in the initial 100 minutes of taking the drugs, and at all but the 20-minute and 240-minute sample time points, the DehydraTECH GLP-1 blood glucose levels were reduced more than evidenced by the control group. More so, even 24 hours after dose administration, the blood glucose levels were reduced in the DehydraTECH GLP-1 group by 6.3% relative to baseline. In contrast, that of the control group was only reduced by 0.67%. This evidenced a nearly ten-fold improvement with DehydraTECH GLP-1.

When the subjects were permitted to eat a standardized meal at the 240-minute mark and a standardized snack at the 360-minute mark, glucose levels spiked by 22.7% for the control group, while those in the DehydraTECH GLP-1 group only saw a 5.3% rise. Although this cannot be attributed to DehydraTECH GLP-1’s overall efficacy in achieving sustained blood glucose reduction, it is a plausible explanation for the difference and a pointer to the overall potential of the technology.

While there are still some additional steps to be taken, these positive results are welcome and point to the technology’s potential, specifically in diabetes treatment. In the DIAB-A22-1 animal study, Lexaria demonstrated at least three positive outcomes, which included weight loss in obese diabetic-conditioned animals and improved triglyceride and cholesterol levels. The study also demonstrated an improvement in locomotor activity compared to untreated obese control rats, with no severe health concerns during dosing (https://cnw.fm/2BAmL).

With the results from Lexaria’s DehydraTECH GLP-1, the company is on track to replicate the positive results from its diabetes study. More importantly, it is on track to carve out a decent market share in an industry projected to bring between $150 billion and $200 billion a year (https://cnw.fm/eV0fW). By doing so, it will also ensure that GLP-1 drugs are more effective with reduced side effects while also being accessible to individuals living with diabetes. It also hopes it will improve the quality of life of people living with the condition by offering a less intrusive and less painful treatment alternative than what is currently in the market.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — German Lawmakers to Vote on Revised Cannabis Legalization Measure Next Week

Legislators in Germany have decided to revise a bill to legalize cannabis in the country, a week before they cast their final vote on it in parliament. The bill to legalize marijuana is being championed by Health Minister Karl Lauterbach, who first discussed details concerning the revised legalization measure in April 2022. In May of the same year, he presented the legislative text to cabinet officials.

When responding to early criticism of the measure from law enforcement and medical groups, Lauterbach emphasized that marijuana reform would be implemented together with a campaign to educate the public on the risks of using marijuana. Last week, Kirsten Kappert-Gonther of the Green Party stated that the resolution would be revised in ways that would make it better.

The amendments would relax some provisions that were challenged by advocates and supporters in the Bundestag. After the resolution is amended, individuals found possessing between 25–30 grams of marijuana won’t automatically be treated as criminal offenders but as administrative violators. The possession limit for home-grown cannabis will also be increased to 30 grams from 25 grams.

With regard to public consumption of marijuana, individuals will not be allowed to use marijuana within 100 meters distance of a school. Prior to the amendment, this figure stood at 200 meters. Legislators also agreed that social clubs that could distribute cannabis to members may begin launching in July 2024 while home cultivation and possession of marijuana legal for adults would begin in April of next year.

Kristine Lütke, a member of the Free Democratic Party in the Bundestag, added that these revisions could bring relief to consumers and make the bill even better. In addition, legislators plan to introduce a complementary resolution that would create pilot programs for commercial sales in different cities across Germany.

Currently, it is expected that once the Bundestag approves the legalization bill, the measure may be advanced to the Bundesrat. In September of this year, members of the Bundesrat had tried and failed to block the proposed measure.

While the Federal Cabinet approved the measure’s initial framework last year, the government thought it best to receive approval from the European Union before enacting it, so they were sure they wouldn’t be violating any global obligations.

In other news, government officials from some countries, including America, met in Germany this previous week to discuss global cannabis policy issues. Last year, Narcotics Drugs Commissioner Burkhard Blienert and a group of German legislators visited the United States and toured marijuana businesses in California to help inform their approach to legalization.

When the German cannabis market finally opens, there will be a chance for local companies grow to the levels seen by enterprises such as Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) that are operating in mature marijuana markets.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Missouri Companies Sell Cannabis Products Worth $1B in 2023

Missouri’s cannabis industry has surpassed $1 billion in sales of medical and recreational marijuana products for the year 2023, as disclosed by the state’s Department of Health and Senior Services (DHHS). In October alone, retailers transacted approximately $95.5 million in recreational cannabis products and an additional $17.6 million in medical cannabis.

Although these figures reflect a slight decrease compared to the previous month, they contribute to the overall 2023 sales, pushing the state’s total marijuana revenue beyond $1.1 billion.

The trajectory of adult-use cannabis sales has exhibited a gradual increase since the commencement of sales in February. Conversely, the sales of medical cannabis have experienced a consistent decline. Notably, there has been a reduction in the number of registered medical cannabis patient cultivators, caregivers and patients throughout the year.

Cumulatively, all cannabis sales in Missouri since 2020 amount to $1.7 billion, according to the DHHS. These figures are, however, approximations, deviating from the conventional reporting format of most states, as Missouri’s DHHS rounds the numbers to the nearest $100,000.

As part of the state’s utilization of tax revenue, lawmakers recently announced the allocation of $17 million to support veterans’ drug treatment, health and legal aid initiatives.

Missouri’s cannabis industry has encountered significant challenges this year, including the recall of thousands of marijuana products due to the alleged illegal use of hemp-derived cannabinoids from outside Missouri. Regulators moved to revoke the business license of Delta Extraction, a company central to the incident. This development raised concerns, particularly regarding practices at product testing labs, which had faced criticism earlier in the year for alleged lab shopping to achieve higher THC potency numbers.

The state, however, rescinded the recall of nearly 15,000 products last month, allowing the products to be returned to dispensary shelves after a storage mandate since early August. The state’s marijuana regulator stated last month that a review of product-tracking records confirmed some recalled marijuana products contained THC sourced exclusively from Missouri’s regulated market.

Moreover, a cannabis retailer, Point Management, operating as Shangri-La, Columbia, recently settled a dispute with a union, resolving 15 charges of unfair labor practices. The settlement mandates the reinstatement of five employees and requires the retailer to compensate more than $145,000 in back pay, front pay, interest and damages for direct or foreseeable financial harm to 10 employees.

In a separate development, legislators criticized the state’s marijuana regulators for exceeding their authority in setting new rules on product branding and packaging aimed at reducing appeal to children.

The booming sales registered in Missouri may depict the broad success that established cannabis companies such as TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF) are enjoying in the markets in which they operate.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — AMA Study Contradicts Claims That Drug Overdose Prevention Centers Fuel Crime

New research has found that overdose prevention centers in New York City have not led to an increase in crime. This is despite concerns that the establishment of harm-reduction centers would cause crime to skyrocket. The new findings add to previous research that demonstrated the centers’ potential in decreasing overdose deaths.

Overdose-prevention centers allow individuals to use illegal substances in a supervised environment, helping reduce the risk of harms associated with drug use, such as a fatal overdose.

The study was carried out by researchers at Brown University, the University of Pennsylvania and the University of Connecticut. For their research, the investigators examined crime trends in NYC’s first government-sanctioned overdose prevention centers, which were launched two years ago. They then compared their findings to areas close to more than 15 syringe service programs that did not provide resources to prevent overdose.

The researchers also analyzed 311 and 911 calls, drug-possession arrests, public nuisances, law enforcement summons for criminal infractions and medical events. They observed no considerable increases in calls for emergency services or crimes recorded by law enforcement in neighborhoods where the prevention centers were located.

In addition, they recorded no statistically significant spike in either violent or property crime near these overdose prevention centers. This is despite a reduction in the number of drug-possession arrests made as the state continues to reprioritize law enforcement.

In their report, the researchers stated that statistically significant decreases in narcotics enforcement by the police around these centers was observed, adding that this was consistent with NYC’s commitment to ensuring that individuals could access the centers without any interference by the police. The researchers also noted that more studies were needed to establish that overdose-prevention centers wouldn’t be linked to localized increases in disorder and crime in the long-term.

At the moment, however, the findings strengthen arguments from harm-reduction advocates on the minimal risk associated with using overdose-prevention sites to help alleviate the risk of overdose deaths, as the opioid crisis rages on.

The research’s findings were published by the American Medical Association in “JAMA Public Health.”

A separate study published in 2022 determined that trained staff intervened in more than 100 overdose instances two months after the first overdose prevention center was launched in NYC. The staff are said to have alleviated risks of overdose by administering oxygen and naloxone as well as offering other services to prevent death. Naloxone is a medication that has been approved by the FDA to reverse an opioid overdose.

The positive role that overdose-prevention centers are playing, contrary to the views of detractors, may mirror the positive impact that marijuana companies such as SNDL Inc. (NASDAQ: SNDL) are having in spite of prohibitionists’ alarmist claims that legalizing cannabis does more harm than good to society.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Study Finds Cannabis Gives Anxiety Sufferers Better Sleep Compared to Alcohol

A recent study supported by federal funding has uncovered insights into the sleep patterns of individuals dealing with anxiety, revealing that the use of marijuana appears to be linked to improved sleep quality. The research, published in the “Drug and Alcohol Review” journal and conducted collaboratively by teams from the University of Haifa, Colorado State University and the University of Colorado, sought to explore the subjective sleep experiences of 347 individuals utilizing cannabis to manage anxiety.

Over a span of 30 days, participants were engaged in daily surveys where they documented their substance use and recounted their previous night’s sleep experience. The study compared outcomes on days with no substance use, marijuana-only use, alcohol-only use and co-use of both substances.

The findings indicated a notable difference in reported sleep quality, with participants reporting better sleep on marijuana-only days and co-use days in contrast to nonuse days. Intriguingly, alcohol-only use did not exhibit a similar positive association with sleep quality. The study also revealed a correlation between the frequency of alcohol and cannabis use and sleep patterns. Individuals with higher usage frequencies reported enhanced sleep quality on days when marijuana was the sole substance used compared to those who used alcohol and cannabis less frequently.

This correlation challenges the idea that tolerance may diminish the sleep-inducing effects of cannabis, as the study suggests an opposite trend of improved sleep quality with more frequent marijuana use. In addition, contrary to the common belief that alcohol aids in sleep, the research corroborated previous findings that alcohol does not contribute significantly to overall sleep quality, especially when juxtaposed with cannabis.

The study posited that understanding various cannabis combinations and ratios remains limited, emphasizing the need for further research, especially in clinical trials. The inclusion of diverse cannabis types, varying in dosage and product selection, prompted the researchers to acknowledge existing gaps in knowledge, advocating for future trials to address these uncertainties.

The study concluded by emphasizing the urgency of experimental investigations into the effects of cannabis and alcohol on sleep. It underscored the potential positive impact of cannabis on subjective sleep quality for individuals dealing with anxiety. Additionally, it highlighted the need for further exploration into the interplay between the frequency of substance use and its immediate influence on sleep, especially in populations seeking cannabis as a coping mechanism for anxiety, where alcohol and cannabis misuse may be prevalent.

As the health benefits of cannabis gain more attention from the scientific community, demand could grow much faster, which could in turn boost the demand for ancillary services such as those offered by Innovative Industrial Properties Inc. (NYSE: IIPR).

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Building a Global Presence with Superior Delivery Technology for Wide Range of Drugs and Active Pharmaceutical Ingredients

Lexaria, a global innovator in drug delivery platforms, has, through its patented DehydraTECH(TM) technology, proven to enhance the performance of several categories of fat-soluble active molecules and drugs
Since 2018, human clinical studies on the technology have yielded positive results, ultimately earning Lexaria 37 granted patents globally, with many more pending around the world
With the strides made so far, Lexaria looks to grow its revenue and commercial opportunities through licensing

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, remains committed to its mission to provide healthier delivery methods of drugs and other Active Pharmaceutical Ingredients (“APIs”). This is made possible through its patented drug delivery technology, DehydraTECH(TM), proven to enhance the performance of several categories of fat-soluble active molecules and drugs across oral and/or topical product formats.

The company’s efforts have focused on several key segments, including hypertension, diabetes, antivirals, epilepsy, nicotine replacement, and more. This has been an ongoing process since 2016, with positive results achieved from various clinical studies thus far, showing up to 17x brain absorption improvements for oral administration of APIs. In 2021, for instance, the nicotine oral mucosal animal absorption study, NIC-A21-1, demonstrated a 10x to 20x reduction in time to deliver peak levels of nicotine, as well as a 1.7x to 6.6x improvement in nicotine levels in the bloodstream (https://cnw.fm/7orZ4).

This is enabled by DehydraTECH’s specific design for formulating and delivering lipophilic drugs and APIs. By increasing their effectiveness and improving the way they enter the bloodstream, DehydraTECH can offer a wide range of benefits, such as a significant increase in bioavailability, increased brain absorption, improving the speed of onset, masking unwanted tastes, and reduced drug administration costs.

Human clinical studies have been conducted since 2018, with more on the way, ultimately earning Lexaria 37 granted patents globally, with many more pending around the world. From 2018 to 2022, four human clinical studies on the potential treatment of hypertension were completed, evidencing lower blood pressure (“BP”) with zero serious adverse events. Lexaria is now closer than ever to submitting its Investigational New Drug (“IND”) application for its planned U.S. Phase 1b Hypertension Clinical Trial with the U.S. Food and Drug Administration.

For the first half of the 2023 calendar year, animal studies on using DehydraTECH-processed CBD for potentially treating diabetes demonstrated positive results such as reduced triglyceride levels, weight loss, and improved cholesterol levels. . .

“This is a remarkable achievement that speaks to the capabilities of the DehydraTECH technology and also to the Lexaria R&D team, working ardently with scarce resources relative to global multi-billion-dollar behemoths,” noted Chris Bunka, Lexaria’s CEO (https://cnw.fm/xOuDJ).

With the strides made, Lexaria looks to grow its revenue and commercial opportunities through licensing. Given its versatile application areas, the technology can be licensed by both the consumer-packaged goods industry and the drug and pharmaceutical sector. Its suitability cuts across a growing range of consumer product formats, such as registered drugs, nutraceuticals, oral suspensions, topical applications, capsules, pills, tablets and more.

The progress achieved thus far by Lexaria is remarkable. Its goals are also much more significant, as evidenced by the time and resources invested into DehydraTECH development. The efforts so far affirm the company’s commitment to providing healthier delivery methods for drugs and other APIs. They also assert its commitment to creating shareholder value and stamping its position as a leader in its segment.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com